Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
NVCR - NovoCure Limited
Market Cap 3.20B P/E - EPS this Y 31.30% Ern Qtrly Grth -
Income -168.7M Forward P/E -4.88 EPS next Y -5.20% 50D Avg Chg -37.00%
Sales 549.96M PEG -0.19 EPS past 5Y - 200D Avg Chg -56.00%
Dividend N/A Price/Book 7.72 EPS next 5Y 60.00% 52W High Chg -75.00%
Recommedations 2.40 Quick Ratio 6.20 Shares Outstanding 108.22M 52W Low Chg 1.00%
Insider Own 9.23% ROA -9.30% Shares Float 98.55M Beta 0.71
Inst Own 86.68% ROE -43.40% Shares Shorted/Prior 6.11M/6.48M Price 30.09
Gross Margin 75.96% Profit Margin -30.68% Avg. Volume 1,519,335 Target Price 27.17
Oper. Margin -22.35% Earnings Date Oct 30 Volume 1,276,382 Change -7.84%
Healthcare | Medical Devices | Jersey
About NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NovoCure Limited News
12/14/24 Novocure price target raised to $42 from $28 at Piper Sandler
12/06/24 Why NovoCure Stock Was Winning Big This Week
12/05/24 Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
12/03/24 Novocure Stock Earns 96 RS Rating
12/03/24 NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
12/03/24 Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
12/02/24 Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds
12/02/24 Novocure seeks approval after pancreatic cancer wearable scores at Phase III
12/02/24 NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
12/02/24 Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success
12/02/24 Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
12/02/24 Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
11/27/24 Novocure to Participate in Upcoming Investor Conferences
11/21/24 Novocure secures FDA approval for add-ons to brain cancer treatment wearable
11/21/24 Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
11/21/24 FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
10/31/24 NovoCure’s Strong Q3 and Leadership Changes in 2024
10/31/24 NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
10/30/24 NovoCure (NVCR) Q3 2024 Earnings Call Transcript
10/30/24 NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Shah Pritesh Chief Growth Officer Chief Growth Officer Nov 07 Sell 12.65 382 4,832 124,511 11/08/23
Weinberg Uri Chief Science Office.. Chief Science Officer Jan 05 Sell 117 8,143 952,731 43,286 01/09/23
Weinberg Uri Chief Science Office.. Chief Science Officer Jan 05 Option 47.04 1,946 91,540 49,050 01/09/23
Leonard Frank X President, CNS Cance.. President, CNS Cancers US Jan 05 Sell 113 39,507 4,464,291 46,158 01/09/23
Leonard Frank X President, CNS Cance.. President, CNS Cancers US Jan 05 Option 15.06 35,209 530,248 53,341 01/09/23
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Jan 05 Sell 108 387 41,796 82,843 01/09/23
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Jan 05 Sell 115.25 212,500 24,490,625 13,583 01/09/23
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Jan 05 Option 9.31 212,500 1,978,375 201,083 01/09/23
Leonard Frank X President, CNS Cance.. President, CNS Cancers US Sep 29 Sell 77.35 6,754 522,422 57,134 09/30/22
Leonard Frank X Chief Development Of.. Chief Development Officer Sep 09 Sell 88 1,863 163,944 84,150 09/12/22
Burke William Patrick Chief Human Resource.. Chief Human Resources Officer Sep 02 Sell 79.037 718 56,749 55,486 09/06/22
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Sep 02 Sell 79.037 885 69,948 72,376 09/06/22
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 02 Sell 79.037 296 23,395 165,024 09/06/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Sep 02 Sell 79.037 269 21,261 83,230 09/06/22
DOYLE WILLIAM F Executive Chairman Executive Chairman Aug 02 Sell 69.659 837 58,305 551,176 08/03/22
Benaim Ely Chief Medical Office.. Chief Medical Officer Aug 02 Sell 69.659 437 30,441 34,631 08/03/22
Leonard Frank X Chief Development Of.. Chief Development Officer Aug 02 Sell 69.659 414 28,839 102,193 08/03/22
Benaim Ely Chief Medical Office.. Chief Medical Officer May 10 Sell 63.2 4,205 265,756 34,846 05/12/22
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Mar 03 Option 13.53 5,040 68,191 65,888 03/11/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Jul 31 Option 154.01 3,717 572,455 85,625 03/11/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Jul 31 Sell 71.19 3,669 261,196 83,187 03/11/22
Longsworth Todd Christopher General Counsel General Counsel Mar 03 Sell 72.45 3,067 222,204 64,801 03/07/22
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Mar 03 Sell 72.45 1,705 123,527 61,607 03/07/22
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Mar 03 Sell 72.75 5,543 403,253 89,683 03/07/22
Benaim Ely Chief Medical Office.. Chief Medical Officer Mar 03 Sell 72.45 2,313 167,577 43,257 03/07/22
Burke William Patrick Chief Human Resource.. Chief Human Resources Officer Mar 03 Sell 72.45 1,367 99,039 57,028 03/07/22
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Mar 03 Sell 72.45 3,870 280,382 168,025 03/07/22
Leonard Frank X Chief Development Of.. Chief Development Officer Mar 03 Sell 72.45 1,485 107,588 103,039 03/07/22
DOYLE WILLIAM F Executive Chairman Executive Chairman Apr 15 Sell 203.1 95,000 19,294,500 555,393 04/15/21
LEUNG GABRIEL Director Director Apr 15 Option 31.45 6,000 188,700 78,045 04/15/21
LEUNG GABRIEL Director Director Apr 15 Sell 199.01 6,000 1,194,060 72,045 04/15/21
Benaim Ely Chief Medical Office.. Chief Medical Officer Apr 15 Option 66.74 5,958 397,637 36,733 04/15/21
Benaim Ely Chief Medical Office.. Chief Medical Officer Apr 15 Sell 200 5,958 1,191,600 33,259 04/15/21
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Mar 05 Sell 144.17 4,832 696,629 97,986 03/05/21
Cordova Ashley Chief Financial Offi.. Chief Financial Officer Mar 04 Sell 152.05 428 65,077 27,249 03/04/21
Shah Pritesh Chief Commercial Off.. Chief Commercial Officer Mar 04 Sell 152.05 912 138,670 91,932 03/04/21
Weinberg Uri Chief Science Office.. Chief Science Officer Feb 24 Option 7.15 6,500 46,475 34,097 02/24/21
Weinberg Uri Chief Science Office.. Chief Science Officer Feb 24 Sell 175.5 6,500 1,140,750 27,597 02/24/21
Benaim Ely Chief Medical Office.. Chief Medical Officer Dec 22 Option 65.43 2,484 162,528 30,007 12/22/20
Benaim Ely Chief Medical Office.. Chief Medical Officer Dec 22 Sell 156.71 2,484 389,268 29,356 12/22/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Dec 22 Option 22 207,910 4,574,020 301,587 12/22/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Dec 22 Sell 160.5 207,910 33,369,555 197,632 12/22/20
Weinberg Uri Chief Science Office.. Chief Science Officer Sep 28 Option 9.31 15,250 141,978 34,097 09/28/20
Weinberg Uri Chief Science Office.. Chief Science Officer Sep 28 Sell 103.35 15,250 1,576,088 27,597 09/28/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 21 Option 7.48 8,262 61,800 150,869 09/21/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 21 Sell 109.15 8,262 901,797 142,607 09/21/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 18 Option 7.26 34,512 250,557 155,107 09/18/20
GROENHUYSEN WILHELMUS CM Chief Operating Offi.. Chief Operating Officer Sep 18 Sell 107.78 34,512 3,719,703 142,607 09/18/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Sep 17 Option 22 103,000 2,266,000 300,632 09/17/20
Danziger Asaf Chief Executive Offi.. Chief Executive Officer Sep 17 Sell 99 103,000 10,197,000 197,632 09/17/20